A study of the association of serum uric acid levels with alanine aminotransferase and gamma-glutamyl transferase levels in non-alcoholic fatty liver disease patients diagnosed by imaging studies
DOI:
https://doi.org/10.18203/2349-3933.ijam20212404Keywords:
Cirrhosis, Hyperuricemia, Liver failure, Non-alcoholic fatty liver disease, SteatosisAbstract
Background: Non-alcoholic fatty liver disease (NAFLD) is a condition defined by excessive fat accumulation in the form of triglycerides (steatosis) in the liver. In recent years, an association between elevated serum uric acid concentrations and NAFLD has been reported. The aim of the study was to perform cross-sectional study to determine the association between serum uric acid levels and the levels of serum alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT), in NAFLD patients.
Methods: In this hospital-based cross-sectional study, 300 patients with diagnosed NAFLD were included during the one-year period from July 2015 to June 2016.
Results: Elevation of alanine aminotransferase levels was seen in a total of 93 cases (31%) and elevation of GGT levels in NAFLD patients was seen in 112 patients out of a total of 300 (37.33%). Hyperuricemia was observed in 99 cases out of a total of 300 cases of NAFLD (33%). A significant association was observed between the two parameters.
Conclusions: The prevalence rate of NAFLD was significantly higher in subjects with hyperuricemia than that in those without hyperuricemia (78.19% versus 40.83 %) (p<0.001), and the prevalence rate increased with progressively higher serum uric acid levels (p<0.001). The relationship between rising uric acid levels with rising ALT and GGT levels in these patients was also found to be statistically significant.
References
Brecque DR, Abbas Z, Anania F, Ferenci P, Khan AG, Goh KL, et al. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol. 2014;48(6):467-73.
Noureddin M, Loomba R. Nonalcoholic fatty liver disease: Indications for liver biopsy and noninvasive biomarkers. Clin Liver Dis. 2012;1(4):104-7.
Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL, et al. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences?. J Gastroenterol Hepatol. 2007;22(6):788-93.
Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med. 1988;27(2):142-9.
Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37(5):1202-19.
Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011;54(1):344-53.
Vijaya G, Benerji D. Comparative Study of ALT, AST, GGT & Uric Acid Levels in Liver Diseases. IOSR J Dent Med Sci. 2013;7(5):72-5.
Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab. 2002;87(7):3023-8.
Parks EJ, Hellerstein MK. Thematic review series: patient-oriented research. Recent advances in liver triacylglycerol and fatty acid metabolism using stable isotope labeling techniques. J Lipid Res. 2006;47(8):1651-60.
Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003;38(10):954-61.
Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol. 2005;43(3):508-14.
Sagi S, Nitzan KD, Halpern Z, Oren R. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int. 2006;26(7):856-63.
Zhou YJ, Li YY, Nie YQ, Ma JX, Lu LG, Shi SL, et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol. 2007;13(47):6419-24.
Sertoglu E, Ercin CN, Celebi G, Gurel H, Kayadibi H, Genc H, et al. The relationship of serum uric acid with non-alcoholic fatty liver disease. Clin Biochem. 2014;47(6):383-8.
Petta S, Camma C, Cabibi D, Marco V, Craxi A. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;34(7):757-66.
Xu C, Yu C, Xu L, Miao M, Li Y. High serum uric acid increases the risk for nonalcoholic Fatty liver disease: a prospective observational study. PLoS One. 2010;5(7):11578.
Sanyal D, Mukherjee P, Raychaudhuri M, Ghosh S, Mukherjee S, Chowdhury S. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metab. 2015;19(5):597.
Afzali A, Weiss NS, Boyko EJ, Ioannou GN. Association between serum uric acid level and chronic liver disease in the United States. Hepatology. 2010;52(2):578-89.
Lee YJ, Lee HR, Lee JH, Shin YH, Shim JY. Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults. Clin Chem Lab Med. 2010;48(2):175-80.
Rao BR, Kumar SV, Ambica DK, Rao RJ. Study Of Biochemical Markers In Non Alcoholic Fatty Liver Disease. Int J Pharma Bio Sci. 2012;2(2):1-7.
Chen S, Guo X, Yu S, Sun G, Yang H, Li Z, et al. Association between Serum Uric Acid and Elevated Alanine Aminotransferase in the General Population. Int J Environ Res Public Health. 2016;13(9):841.
